Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.
about
Hematopoietic stem cell transplantation for MDS.Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrosRole and timing of hematopoietic cell transplantation for myelodysplastic syndrome.Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CYTransplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsCurrent status of allogeneic hematopoietic cell transplantation for MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Optimization of allogeneic transplant conditioning: not the time for dogma.The hematopoietic system in the context of regenerative medicine.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Peripheral-blood stem cells versus bone marrow from unrelated donorsIs mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.The evolution of hematopoietic SCT in myelodysplastic syndrome.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.Therapeutic spectrum in the treatment of myelodysplastic syndromes.Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.Mobilized peripheral blood cells administered intravenously produce functional recovery in stroke.Aerobic exercise in humans mobilizes HSCs in an intensity-dependent manner.A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignThe bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS.Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAssociation of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplantsPeripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry
P2860
Q33767314-9FC28B4E-B9F3-4C38-8123-387B5105C5CDQ34272525-2209A63C-6F6C-41B1-8009-056CDEE2D47BQ34549306-79978968-D881-43D6-B2F8-A68DB3974D22Q35739130-4A94C23F-C6D0-44C5-B364-6C0815F7F50DQ35838113-FDF6EEE3-CE89-429A-8863-D55AA2AC3F85Q36063049-53911694-B318-42F3-AAD8-634DCBDB0DB9Q36431041-10E0DC3A-F848-48B1-AC2C-A5086EE395EFQ36556498-7C3BBD52-F2BA-490F-BF76-EF22F69CD150Q36627127-36695284-42EF-47A1-A9BC-E4782B12FA56Q36811828-FD0E8245-D185-41F2-A768-A21680D0CAAFQ36915850-3FC2BEBE-9038-48E6-B7DF-BFF683033799Q37110816-99657E38-B1A6-4C31-9672-CDB73B450F86Q37263146-DBFD865A-2B1B-4E10-AA75-8AB015606B91Q37276359-F50C973A-3B7F-4877-AA60-9FF0962BBB15Q37334978-E6D58427-D99B-443A-96A5-D03ED683B1FAQ37404489-F2570C7C-A20D-4A97-94E0-CEADEC653853Q37707098-176AE57E-DFC8-4683-A661-6F2A80073BFEQ37937045-DD1EB354-DA98-41E0-9E25-ADA04738AFCFQ37964938-07A169EA-D257-4734-921F-DF50651BCC7AQ39092515-D45B6760-DB72-41BD-B61D-FA7A789E7CDBQ39209778-0301A5F9-F3BA-4215-95A0-7907C322B528Q40464419-F3D76790-5BEC-458E-ADDD-EEEC3C89AEC4Q40766061-4BC5B495-F097-490D-8758-E3897EA7A03DQ46397677-4E99B9E5-305A-4067-BBCE-5FE225D56E69Q48226649-0E7D8DB3-E7D2-4810-BF94-53E663539370Q48229759-F2B6F6CF-DC4E-4DAF-A6E7-372E7FD35829Q51048096-99061457-42A2-4743-A525-0F5D2E57D783Q51981153-B9E44AD4-1F0D-46B0-A3ED-089307AABBC4Q52897534-7D2EC745-7C2A-430E-BFD5-3B50C717A791Q53528762-1DE5D727-2D23-405E-9EA7-6456D0248EEFQ55969986-3C478004-2271-4397-8735-021C5DD6BF4AQ58814284-7314DB6B-B467-4F33-9CA1-9E136F130B13Q58865961-B566AC12-2BCF-4FC3-AD69-FBECD5D78BB2
P2860
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@ast
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@en
type
label
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@ast
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@en
prefLabel
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@ast
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@en
P2093
P50
P1433
P1476
Retrospective comparison of bo ...... in myelodysplastic syndromes.
@en
P2093
Andrea Bacigalupo
Anja van Biezen
Dietger Niederwieser
Enric Carreras
Harry C Schouten
Jan J Cornelissen
Jürgen Finke
Marc A Boogaerts
Philippe Guardiola
Ronald Brand
P304
P356
10.1182/BLOOD.V99.12.4370
P407
P577
2002-06-01T00:00:00Z